Table 2.
Baseline patient characteristics
| Characteristic | No. (%)a of patients with each characteristic receiving: |
|
|---|---|---|
| Omadacycline (n = 111) | Linezolid (n = 108) | |
| Male sex | 66 (59) | 57 (53) |
| Race | ||
| Caucasian | 97 (87) | 99 (92) |
| Black | 8 (7) | 6 (5) |
| Other | 6 (5) | 3 (3) |
| Age (yr) | ||
| 18–44 | 51 (46) | 50 (46) |
| 45–64 | 50 (45) | 48 (44) |
| ≥65 | 10 (9) | 10 (9) |
| Infection diagnosis | ||
| Major abscess | 73 (66) | 72 (67) |
| Wound infection | 21 (19) | 17 (16) |
| Lower extremity ulcer | 9 (8) | 9 (8) |
| Cellulitis | 8 (7) | 10 (9) |
| Mean maximal linear dimension of infection (SD) (cm) | 14.2 (13.5) | 12.0 (11.5) |
| Mean no. of days of study therapy (SD) | 10.0 (3.9) | 9.6 (4.4) |
| Mean no. of days of intravenous therapy (SD) | 4.3 (2.4) | 4.3 (3.4) |
| Signs and symptoms assessed as moderate or severeb | ||
| Erythema | 90 (81) | 83 (77) |
| Edema/induration | 85 (77) | 72 (67) |
| Fluctuance | 30 (27) | 26 (24) |
| Necrotic tissue | 11 (10) | 5 (5) |
| Purulence | 36 (32) | 33 (31) |
| Tenderness/pain | 102 (92) | 96 (89) |
| No. with each pathogen identified as the cause of infection in the ME populationc | ||
| S. aureus | 72 | 55 |
| MRSA | 44 | 32 |
| Gram-positive bacterium other than S. aureus | 3 | 7 |
| Gram-negative bacterium | 2 | 1 |
a
Values are numbers (percentages) unless otherwise indicated.
b
Data missing on 2 linezolid-treated patients.
c
The total number of patients in the ME population who were treated with omadacycline is 77, and the total number treated with linezolid is 63.